Diptoindonesin G, a new Hsp90 drug

被引:3
|
作者
Wickramaratne, Anushka [1 ]
Wickner, Sue [1 ]
机构
[1] NCI, Lab Mol Biol, NIH, Bethesda, MD 20814 USA
关键词
D O I
10.1016/j.jbc.2022.102826
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Hsp90 is a molecular chaperone that participates in protein folding, activation, and stabilization of substrate proteins. Since many diseases, including cancer, neurodegenerative dis-eases, and metabolic diseases, are caused by protein misfolding, drugs that inhibit Hsp90 are being pursued as potential targets for treatments. In the recent JBC Editor's Pick by Donahue et al., the authors show that diptoindonesin G is a new Hsp90 inhibitor that promotes degradation of the estrogen receptor, an Hsp90 client, without inducing the heat shock response.
引用
收藏
页数:2
相关论文
共 50 条
  • [1] Diptoindonesin G is a middle domain HSP90 modulator for cancer treatment
    Xu, Wei
    Donahue, Kristine
    Xie, Haibo
    Li, Miyang
    Gao, Ang
    Ma, Min
    Li, Shunqiang
    Li, Lingjun
    Tang, Weiping
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2023, 299 (03) : S78 - S78
  • [2] Diptoindonesin G is a middle domain HSP90 modulator for cancer treatment
    Donahue, Kristine
    Xie, Haibo
    Li, Miyang
    Gao, Ang
    Ma, Min
    Wang, Yidan
    Tipton, Rose
    Semanik, Nicole
    Primeau, Tina
    Li, Shunqiang
    Li, Lingjun
    Tang, Weiping
    Xu, Wei
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2022, 298 (12)
  • [3] Hsp90: A Drug Target?
    Jeffrey M. Holzbeierlein
    Andrew Windsperger
    George Vielhauer
    Current Oncology Reports, 2010, 12 : 95 - 101
  • [4] Hsp90: A Drug Target?
    Holzbeierlein, Jeffrey M.
    Windsperger, Andrew
    Vielhauer, George
    CURRENT ONCOLOGY REPORTS, 2010, 12 (02) : 95 - 101
  • [5] Hsp90 reaches new heightsConference on the Hsp90 Chaperone Machine
    Avrom J Caplan
    Sophie Jackson
    David Smith
    The EMBO Reports, 2003, 4 (2): : 126 - 130
  • [6] Hsp90 as a target for drug development
    Chaudhury, Subhabrata
    Welch, Timothy R.
    Blagg, Brian S. J.
    CHEMMEDCHEM, 2006, 1 (12) : 1331 - +
  • [7] Mutations that increase both Hsp90 ATPase activity in vitro and Hsp90 drug resistance in vivo
    Zurawska, Anna
    Urbanski, Jakub
    Matuliene, Jurgita
    Baraniak, Janina
    Klejman, Marcin P.
    Filipek, Slawomir
    Matulis, Daumantas
    Bieganowski, Pawel
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2010, 1803 (05): : 575 - 583
  • [8] The role of Hsp90 in Gα12 signaling
    Vaiskunaite, R
    Sessa, W
    Kozasa, T
    Voyno-Yasenetskaya, S
    FASEB JOURNAL, 2001, 15 (04): : A206 - A206
  • [9] Drug discovery and research of Hsp90 inhibitor
    Soga, Shiro
    Nakashima, Takayuki
    Seike, Toshihiro
    Ishii, Toshihiko
    Shiotsu, Yukimasa
    Akinaga, Shiro
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2012, 118 : 36P - 36P
  • [10] Overview: Translating Hsp90 Biology into Hsp90 Drugs
    Workman, Paul
    CURRENT CANCER DRUG TARGETS, 2003, 3 (05) : 297 - 300